Abstract

Glaukos Corporation will report second-quarter 2026 financial results on July 29, 2026 Post-Mkt, with investor focus on whether strong revenue momentum and improving losses seen last quarter can continue while newly clarified reimbursement and recent product launch execution shape the outlook.

Market Forecast

Consensus for the current quarter projects Glaukos Corporation’s revenue at 150.95 million US dollars, up 30.68% year over year, with adjusted EPS of -0.22 improving 15.63% year over year and an EBIT loss of 13.72 million US dollars improving 17.24% year over year; the company’s prior report also raised full-year 2026 sales guidance to a range of 620.00–635.00 million US dollars. The core commercial engine is expected to remain steady on procedural and implant growth and expanding uptake for new therapies, supporting sequential consistency in topline while the cost base and launch investments shape near-term losses. The most promising segment is Glaucoma, which generated 129.26 million US dollars last quarter; management targets approximately 30% year-over-year growth for its US glaucoma business in 2026, implying continued robust momentum into the current quarter.

Last Quarter Review

Glaukos Corporation delivered first-quarter 2026 revenue of 150.57 million US dollars (up 41.16% year over year), a gross profit margin of 77.86%, a GAAP net loss attributable to the parent of 19.78 million US dollars with a net margin of -13.14%, and adjusted EPS of -0.18 (improving 18.18% year over year). A key highlight was a broad-based beat versus expectations, with revenue exceeding consensus by 13.66 million US dollars and a narrower-than-expected adjusted loss per share. Main business highlights included Glaucoma products contributing 129.26 million US dollars (85.85% of revenue), with Corneal Health at 21.31 million US dollars (14.15% of revenue), while total company sales rose 41.16% year over year on strong uptake of the company’s key therapies.

Current Quarter Outlook

Main commercial engine

Consensus projects second-quarter 2026 revenue of 150.95 million US dollars, and the prior quarter’s performance sets a high bar for execution. The Glaucoma portfolio continues to anchor the top line with 129.26 million US dollars last quarter, and sentiment around reimbursement clarity and expanding use within approved patient populations has been constructive. The company’s raised full-year revenue outlook of 620.00–635.00 million US dollars embeds a healthy growth cadence for the remainder of the year, and this quarter’s setup appears aligned with that trajectory. From a profitability standpoint, forecasts imply an EBIT loss of 13.72 million US dollars, a year-over-year improvement of 17.24%, consistent with the narrative of scale-driven operating leverage partially offset by commercial investment to support launches and market access work. The near-term path to loss reduction remains closely tied to procedure volumes, channel inventory stability, and the pace of utilization for recently introduced solutions; investors will watch whether the gross margin line remains anchored near last quarter’s 77.86% amid a changing product mix and the incremental costs of expanding therapy availability and support programs.

Most promising growth vector

Corneal Health, supported by Epioxa, is a focal point for incremental growth and medium-term mix enhancement. Last quarter, the segment contributed 21.31 million US dollars, and the company has been preparing the market through market access initiatives, center onboarding, and patient support programs. The cadence of payer coding is a core driver: management has indicated that permanent J-code timing for Epioxa was expected in July 2026, which would simplify billing and drive adoption as more sites become ready to treat patients. In addition, product education and the steady expansion of treatment center coverage are designed to reduce friction for physicians and patients; these steps help translate interest into actual treatment starts. With that infrastructure ramping, the current quarter should show tangible early contributions while still reflecting the typical launch curve characteristics—ongoing demand generation, learning curves across sites, and gradual broadening of payer familiarity—factors that can keep quarter-to-quarter metrics choppy but cumulatively supportive of the full-year outlook.

Key stock drivers this quarter

Three catalysts are likely to have outsized influence on the stock around the print and guide. First, revenue outperformance or confirmation at approximately 150.95 million US dollars with a year-over-year increase of 30.68% would validate that procedure flow, utilization, and access initiatives remain on track; any sign of sustained momentum or upside in the glaucoma franchise would likely be well received. Second, profitability signals will matter: consensus looks for adjusted EPS of -0.22 and an EBIT loss of 13.72 million US dollars; investors will parse commentary on cost discipline, launch spend phasing, and margin puts and takes. The gross margin backdrop—last quarter’s 77.86%—serves as a reference point; mix shifts linked to new therapy ramp and access-related programs could influence the near-term profile. Third, reimbursement and launch execution updates stand out as a narrative driver. Recent commentary has pointed to favorable reimbursement developments for iDose and an expected permanent J-code for Epioxa; confirmation of access expansion, payer coverage breadth, and center activation should shape forward sales visibility. Looking beyond the quarter, clinical and pipeline milestones, such as the completion of phase 2 enrollment for GLK‑321 in Demodex blepharitis, contribute to medium-term optionality without being primary near-term financial drivers.

Analyst Opinions

The view among institutions in the past six months has been decisively bullish, with multiple firms reiterating Buy ratings and raising price targets. Notable calls include Goldman Sachs reiterating Buy with a 153.00 US dollars target, Citi maintaining Buy with a 175.00 US dollars target, Stifel repeating Buy with targets at 160.00–170.00 US dollars, BTIG reiterating Buy with targets at 131.00–162.00 US dollars, Truist lifting its target to 180.00 US dollars while maintaining Buy, and Needham increasing its target to 150.00 US dollars and reiterating Buy. William Blair has consistently reiterated an Outperform/Buy stance, emphasizing attractive risk‑reward as reimbursement visibility improves and product launches progress. Based on collected items, the bullish-to-bearish ratio is overwhelmingly tilted to bullish, with the bullish camp comprising essentially all the referenced published notes.

The core of the bullish thesis centers on three pillars. First, revenue durability: analysts point to the company’s consistent topline execution and the breadth of contribution from multiple commercial and pre-commercial assets. Consensus for the current quarter—150.95 million US dollars, up 30.68% year over year—aligns with that narrative and follows a strong first quarter that grew 41.16% year over year and exceeded expectations. The raised full-year sales outlook to 620.00–635.00 million US dollars serves as a quantitative anchor for the trajectory, and coverage notes broadly view the range as achievable if current trends hold. Second, reimbursement clarity: several notes highlight a favorable local coverage determination for iDose, which reduces uncertainty and supports physician adoption. On the corneal side, the expected permanent J-code for Epioxa is cited as a practical catalyst that should streamline billing and accelerate site activation, thereby enhancing the translation of clinical interest into realized revenue. Analysts stress that reimbursement structures often determine the slope of uptake curves; the mix of positive updates here underpins confidence in the model. Third, multi‑product growth: commentary from BTIG, William Blair, and others emphasizes the value of having several growth drivers at different stages—commercialized glaucoma solutions, a ramping corneal therapy, and pipeline assets such as GLK‑321 that have recently completed phase 2 enrollment. This multi‑engine profile spreads execution risk while sustaining momentum.

The bullish majority also underlines operating leverage as a potential medium‑term benefit. While consensus embeds an EBIT loss of 13.72 million US dollars this quarter, analysts expect loss reduction over time as volumes scale and launch costs normalize. Margin commentary will be watched closely: last quarter’s 77.86% gross margin provides a healthy baseline, and coverage suggests that the interplay between product mix and launch support spending will determine near‑term variability. Should revenue come in near or above expectations while costs remain aligned with plan, coverage generally anticipates sequential improvement in per‑share losses, consistent with the estimated 15.63% year‑over‑year improvement in adjusted EPS for the current quarter.

Finally, analyst notes tie short‑term stock performance to three read‑throughs from the print: the cadence of glaucoma uptick, the early access and coding traction for Epioxa, and the sustainability of the raised 2026 revenue outlook. In practical terms, commentary on procedure trends, reorder patterns, and the breadth of payer approvals will be as influential as the headline numbers. With all collected institutional opinions in the period being positive and several targets clustered between 150.00 and 180.00 US dollars, the majority stance is that the setup for the current quarter remains favorable, with reimbursement progress and multi‑product execution providing the foundation for continued revenue growth and gradual loss reduction.